Axonal degeneration and progressive neurologic disability in multiple sclerosis

Area of Science:

• Neuroscience
• Immunology
• Neurology

Background:

• Accumulating evidence implicates axonal degeneration as the primary driver of irreversible neurological disability in multiple sclerosis (MS).
• Axonal injury in MS correlates with inflammation in active lesions and occurs early, suggesting inflammatory demyelination contributes significantly to axon pathology during the relapsing-remitting stage.
• Axonal loss can precede clinical symptoms for years, with disability manifesting when compensatory mechanisms are overwhelmed.

Purpose of the Study:

• To underscore the neurodegenerative nature of multiple sclerosis (MS).
• To highlight the clinical implications of understanding axonal degeneration in MS.
• To emphasize the need for developing neuroprotective therapies and effective monitoring tools for MS.

Main Methods:

• Review of accumulating data on axonal degeneration in multiple sclerosis (MS).
• Correlation analysis of axonal injury extent with inflammation in active MS lesions.
• Examination of axonal pathology in both demyelinated lesions and normal-appearing white matter.

Main Results:

• Axonal degeneration is the major determinant of irreversible neurological disability in multiple sclerosis (MS).
• Inflammatory demyelination is a key factor in axon pathology during the relapsing-remitting stage of MS.
• Axonal pathology extends beyond lesions into normal-appearing white matter and can be influenced by long-term demyelination.

Conclusions:

• Multiple sclerosis (MS) should be viewed as a neurodegenerative disorder.
• Proactive anti-inflammatory and immunomodulatory treatments are crucial to prevent or delay chronic disability by targeting inflammation-induced axonal injury.
• Further research into axonal degeneration mechanisms is needed for novel neuroprotective therapeutics, with surrogate markers like N-acetyl aspartate aiding in monitoring treatment efficacy.